July 24, 2024
FDA grants RMAT designation to AffyImmune’s AIC100 for thyroid cancer
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation for AffyImmune’s CAR T-cell therapy, AIC100, to treat recurrent anaplastic thyroid cancer (ATC).